Project Grant R21TR005565
Award Date
7/7/25
Completion Date
6/30/27
Dollars Obligated
$374K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
This Project Grant award of $450,000 from the National Science Foundation's Engineering program (CFDA 47.041) to North Carolina State University is for developing bio-censors that can simultaneously quantify capsid and transgene titers in adeno-associated viral (AAV) vectors used for gene therapy. The research aims to: 1) investigate peptide ligands' differential recognition of AAV capsids, 2) engineer extended-gate field effect transistor bio-censors to enhance detection and discrimination, and...
This Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), under the CFDA Number 93.350 National Center for Advancing Translational Sciences program, provides $349,909 to Nanoengineering Corporation to develop a portable benchtop instrument, NanoRanger, that can quickly and accurately measure the size of viral vectors like adeno-associated virus (AAV) at the angstrom scale. This will help the gene therapy industry meet cost reduction goals by enabling...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $275,000 will support the development of a plasmonic nanopore sensor device for quality control of adeno-associated viruses (AAVs) used in gene therapy. The proposed device will enable accurate characterization of AAV payload (single-stranded DNA, double-stranded DNA, or empty) at low, pre-scale-up concentrations to optimize formulations. The project aims to demonstrate the...
This Project Grant award of $1,640,169 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports Synvivia, Inc.'s development of a platform to identify cyclic peptides that can increase the yield and quality of adeno-associated virus (AAV) vectors for gene therapy manufacturing. The key products and services to be delivered include: Demonstrating that Synvivia's cyclic peptide discovery library contains compounds that...
This Project Grant award of $1,405,717 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to better understand the mechanisms and optimize the conditions for cavitation-facilitated adeno-associated virus (AAV) transduction (CFAT) for cardiac gene therapy. The goal is to increase the efficiency of cardiomyocyte-specific AAV transduction to overcome the dose-related safety issues associated with high doses of AAVs in current gene...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $1,158,262 Project Grant (CFDA 93.286) to the University of Massachusetts Medical School to develop a synthetic RNA switch technology that can precisely control the timing and dosage of gene therapies delivered via adeno-associated viral (AAV) vectors. The project aims to optimize a highly efficient, leak-free RNA switch system to regulate transgene expression for therapeutic applications, including dose control of...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
This federal Project Grant award, valued at $419,398, was provided by the National Center for Advancing Translational Sciences (NCATS) under the CFDA Program 93.350 to accelerate the translation of oligonucleotide therapeutics by enhancing delivery. The project aims to develop a small molecule solution to improve the delivery of systemically administered oligonucleotide therapeutics to extrahepatic tissues, a critical unmet need that has limited the broad clinical translation of these...
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Cornell University a $435,412 Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The goal of this 2-year project is to develop a biomaterial-driven, immunosuppressive platform that enables the re-administration of engineered adeno-associated virus (AAV) gene delivery vectors while maintaining their transduction efficiency....